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Abstract: The enduring discussion, why plants produce secondary metabolites with pharmacologically and toxicologically active 
towards mammals traces back to the eminent role of medicinal plants in the millennia-old history of manhood. In recent years, the 
concept of an animal plant warfare emerged, which focused on the co-evolution between plants and herbivores. As a reaction to 
herbivory, plants developed mechanical defenses such as thorns and hard shells, which paved the way for adapted animal physiques. 
Plants evolved further defense systems by producing chemicals that exert toxic effects on the animals that ingest them. As a result 
of this selective pressure, animals developed special enzymes, e.g. cytochrome P450 monooxigenases (CYP450) that metabolize 
xenobiotic phytochemicals. As a next step in the evolutionary competition between plants and animals, plants evolved to produce 
non-toxic pro-drugs, which become toxic only after ingestion by animals through metabolization by enzymes such as CYP450.  
Because these sequestered evolutionary developments call to mind an arms race, the term animal plant warfare has been coined. The 
evolutionary competition between plants and animals may help to better understand the modes of action of medicinal plants and to 
foster the efficient and safe use of phytotherapy nowadays. 
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1 Plant Defense Systems Against Herbivores 
The relevance of animal-plant warfare can be illustrated by 
an apparent example from every-day life: Anyone who has 
ever cut an onion while cooking knows how effectively plants 
can cause reactions: tearing and burning eyes may prevent 
cooks or animals from destroying Allium sativum bulbs. With 
the evolution of this defense mechanism, the plant has won an 
important fight against its enemies. Plants were challenged 
during evolution by microbial attack and herbivores. Lacking 
an immune system such as animals and limited control over 
their movements, they developed a chemical defense system 
with effective toxins.1 The field of chemical ecology has 
emerged during the past two decades and a lot of interactions 
between plants and hervivores have been understood. It has 
been a matter of debate for many decades that evolutionary 
selection leads to optimization of survival strategies and  
adaptation of species on earth (adaptionist programme).2 
Plants have evolved several mechanisms against external  
attacks. Constitutively expressed defenses offer plants  
permanent protection, while inducible defenses are produced 
only in response to environmental stresses such as mammalian 
browsing and insect herbivory.3,4 The variability of  
environments, including attributes such as altitude, temperature
and moisture variations, are further factors influencing plants’ 
armory of defensive weapons.5,6 
The various phytochemicals produced by plants are major 
constraints that limit the ingestion behavior of herbivores and 
thus determine herbivore impact on vegetation. Plant secondary
metabolites (PSMs) such as alkaloids, terpenes, phenolics, 
glucosinolates and cyanogenic glycosides have been shown to 
exert effects on herbivores.7 The biosynthesis of these  
compounds is regulated by genes whose expression and activity
are directly influenced by environmental factors. In this  
context, the influence of fire on the coevolution of plants and 
herbivores has been pointed out.8 Fire is a repeatedly occurring 
disturbance for flora and fauna in some biosystems. It has been 
shown that where fire is greatest, hares are most abundant. 
They feed on juvenile woody plants when vegetation grows 
again after destruction by fire. As an adaptation, birches (Betula
neoalaskana and B. papyrifera) produce more PSM in these 
regions than birches in areas without fire. Hence, geographic 
conditions such as bush fire coincidences with coevolution of 
plants and herbivores.8 
The concentrations of specific hydrocarbons, fatty acids and 
essential oils that a plant produces also depend on other  
environmental conditions.3,9 Increased concentrations of toxic 
compounds may cause directly serious health consequences in 
herbivores. Hence, herbivores must avoid saturating their  
detoxification systems as stated in the detoxification limitation 
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hypothesis.10–12 
PSM of food plants restrict the amount of food taken up by 
animals and thereby affect their reproduction rates.13 Hence, 
PSM reduce fitness of herbivoric predators.13,14 During  
evolutionary development, herbivores reacted by different 
strategies, e.g. development of sophisticated oral sensation of 
the PSM content in a plant15 reduced food intake16 switching 
from diet with high PSM content to another one with less  
concentrations of toxins,17,18 alterations of meal patterns, i.e. 
changing from few daily meals with high food intake to many 
meals with low food intake,19,20 and metabolization and  
detoxification of toxic PSM taken up with food.21–25 Another 
adaptation to PSM that cannot be taken up in unlimited 
amounts is the evolutionary developments of specialists and 
generalists. The mixed diet of generalistic herbivores reduce 
the need for detoxification of similar groups of toxic PSM, 
whereas herbivores specialist to one or few plant species as 
food source developed especially improved metabolic  
detoxification pathways.26–31 
In the past decades, many phytochemicals have been isolated
and investigated for their pharmacological activities. Examples 
include Lamiaceae plants such as lavender (Lavandula  
angustifolia Mille. x L. latifolia Mill.), thyme (Thymus vulgaris
L.), winter savory (Satureja montana L.), rosemary  
(Rosmarinus officinalis L.), sage (Salvia officinalis L.) and 
peppermint (Mentha x piperita L.), all of which contain  
chemical compounds to protect against herbivores (Table 1; 
Figure 1).32 
Mammalian herbivores that ingest plants may suffer from a 
variety of adverse effects. It has been reported that PSMs 
stimulate the emetic center so that herbivores increasingly 
deter these plants by flavor aversion.33 Two specific 
monoterpenoids of thyme basil (Acinos suaveolens, 
Lamiaceae), R-(+)-pulegone (cyclohexanone, 5-methyl-2-(1-
methylethylidene) and menthone (cyclohexanone, 5-methyl-2-
(1-methylethyl)), have been analyzed and provide several 
interesting clues supporting the hypothesis of evolutionary 
animal plant warfare. In a study of plants in Greece, 
significant differences in the concentration of these 
compounds in upper, middle and lower sections of plants on 
accessible and inaccessible rock pillars were found.34 After an 
extracting process, the levels of menthone and pulegone were 
determined by gas chromatography coupled with mass 
spectrometry (GC-MS). The concentrations of menthone were 
similar, whereas plants in the accessible rock location 
contained more R-(+)-pulegone than plants on inaccessible 
rock pillars. Previous experiences have shown that 
invertebrates avoid R-(+)-pulegone-containing Lamiaceae 
plants. These two monoterpenoids possess antimicrobial, 
fungistatic, allelopathic, insecticidal,35 and even psychoactive 
properties.36 Pulegone seems to be more toxic than menthone 
to herbivores. Symptoms such as necrosis, pulmonary edema 
and internal hemorrhage appear after consumption of 
pulegone.37 It has been hypothesized that monoterpenoids 
covalently bind to liver proteins leading to microsomal 
cytochrome P450 damage.38,39 Consequently, xenobiotics are 
unable to be metabolized due to liver dysfunction.  
The toxicity of pulegone was demonstrated in a study on 
pennyroyal tea used against various ailments and as an 
arbotifacient.40 This tea may lead to death in some cases 
because of the high toxicity of pulegone. It has traditionally 
been used to settle an upset stomach, to relieve flatulence, to 
induce sweating, and to treat colds, influenza and abdominal 
cramps. It is also applied for the treatment of diseases such as 
smallpox and tuberculosis and to promote latent menstruation. 
Biochemically, pulegone is a precursor of menthone that is 
synthesized by pulegone reductase.41–43 Genetic modification 
of this enzyme leads to differential processing of chemical 
compounds.42–45 It can be hypothesized that plants easily 
accessible to herbivores, such as those in meadows, reduce the 
expression of pulegone reductase so that the R-(+)-pulegone 
levels are increased. On the other hand, plants on inaccessible 
rock pillars produce less pulegone. Similar inter-individual 
variability as an adaptation against herbivore attack has been 
observed for other terpenoid compounds as well.46,47 
Another example of animal plant warfare is presented by 
Mintosthachys mollis (Lamiaceae), a plant used for medicinal 
infusions and for the preparation of commercial drinks due to 
its peppermint flavoring. It is also a natural biocide used to 
control pests.44 These plants face two different types of insect 
herbivores: the leaf miner Chromatomyia platensis (Brethes) 
(Diptera: Agromyzidae) and the cecydomid gall insect 
(Diptera: Cecydomyiidae).48–50 The concentration of 
terpenoids in different parts of the plant affected by leaf miner 
insect and undamaged leaves as well as leaves from stems with 
and without galls was determined. The monoterpenes pulegone 
and menthone accounted for about 70%.44,51 The leaves that 
had been mined or were growing on gall-bearing stems 
revealed significantly decreased concentrations, whereas both 
categories of undamaged leaves (mined or were growing on 
gall-bearing stems had similar concentrations of pulegone. 
This speaks to a chemical defense reaction against insect-
induced galls and other lesions. Furthermore, the leaves 
growing on a gall-bearing stem showed increased menthone 
Table 1. Important chemical compounds in the Lamiaceae family of plants 
plant chemical compounds
Lavandula angustifolia Mille. x L. latifolia Mill. (lavender) 1,8-cineole, linalool, camphor and linalyl acetate 
Thymus vulgaris L. (thyme) p-cymene, τ-terpinene and thymol 
Satureja montana L. (winter savory) p-cymene, γ-terpinene and carvacrol 
Rosmarinus officinalis L. (rosemary) α-pinene, borneol, 1,8-cineole and camphor 
Salvia officinalis L. (sage) 1,8-cineole, α-thujone, β-thujone and camphor 
Mentha x piperita L. (peppermint) 1,8-cineole, menthone, menthofuran, menthol and pulegone 
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concentration. The accelerated rate of pulegone transformation 
to menthone was understood to be a response to leaf miner 
activity. Similar results were obtained in the presence of galls, 
although other mechanisms were hypothesized. All chemical 
compounds in Mintosthachys mollis were generally recognized 
as safe by the U.S. Food and Drug Administration.52 
These two examples of thyme basil and Mintosthachys 
mollis illustrate the way in which plants respond to animal 
herbivores.53 Mammalian herbivore attacks lead to an increase 
in pulegone concentrations, whereas the content of menthone 
is generally increased when insects attack plants. 
The first plant barriers are the cell wall and the cuticle.6  
Epicuticular waxes,6 although they primary protect from fluid 
loss and high temperatures, also double as important plant 
barriers against external attacks. Another anti-herbivore  
defense mechanism is the development of thorns, spines and 
prickles.54 Many types of thorns are aposematic meaning that 
they are colored, characterized by bright conspicuous  
markings, which mammalians recognize and learn to avoid. 
Mammalian herbivores learn to recognize and avoid the  
distinctive coloration of specific plant parts after repeated  
injury or adverse reaction. 
 
2 Evolutionary Arms Race Between Plants and Herbivores 
Plants use three major levels of strategic defense to protect 
themselves from herbivores (Figure 2). Firstly, physical  
protection consists of thorns, spines and strengthened cell 
walls, which cause ligneous, hard shelled bodies that deter 
animals from galling.7 Secondly, PSMs provide chemical  
protection. PSMs can cause herbivore aversion by bitter taste, 
bad flavor or smell. Furthermore, PSMs can be toxic and  
induce vomiting, illness or dizziness in animals after plant 
consumption. The third defense strategy represents metabolic 
defenses. Many PSMs act as pro-drugs in animals, i.e. they 
need to be metabolized by CYP450 enzymes to deploy their 
toxic effects in the body. Some plants are able to reduce the 
effectiveness of PSM detoxification by inhibiting efflux 
pumps (phase III proteins).55 Efflux transporters have initially 
raised interest in cancer biology and clinical oncology as 
pumps for anticancer drugs that maintain the level of  
anticancer drugs at sublethal concentration in cancer cells 
thereby leading to threatened multidrug resistance phenotypes 
failure of chemotherapy and fatal outcome for cancer  
patients.56–59 More recently, it was recognized that efflux 
transporters play a crucial role for the absorption and  
bioavailability of pharmaceuticals in general and xenobiotic  
compounds taken up with food.12,60,61 This also implies a  
fundamental role of the evolutionary arms race between  
animals and plants. 
On the other hand, animals defend themselves against these 
plant attacks at several strategic levels. Analogous to the  
physical plant defenses, animals developed robust physical 
attributes such as strong dermis, tight furs or coat, strengthened
dentition, etc. At the secondary stage, animals developed  
protective strategies against the chemical toxins produced by 
plants. This includes specific feeding habits to avoid toxic 
plasma levels as well as the development of detoxifying  
mechanisms.7 In detail, there are four steps in plant chemical 
toxicity that can theoretically be countered by mutations. The 
uptake of xenobiotics into a cell is described as “Phase 0”, and 
of course it is in the animals’ best interest to prevent the  
diffusion or uptake of toxic compounds. “Phase I” comprises 
the metabolism of xenobiotics via CYP450 enzymes.  
Adaptation in the enzymes’ structure or in their induction 
leads to increased detoxifying potential. This detoxification 
step represents the single most effective way for animals to 
 
Figure 1.  Chemical structures of selected natural products (taken from Wikipedia) 
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cope with toxic influences from their environment. In “Phase 
II,” the phase I metabolites are coupled with hydrophilic  
substances to increase elimination of toxins. Increased elimi-
nation results in an ability to tolerate higher amounts of toxin 
uptake because it decreases plasma toxin levels.7 Therefore, 
mutations in phase II enzymes that boost their effectiveness 
towards a certain xenobiotic may entail nutritional advantages. 
The forth step that poses an opportunity for evolutionary  
adaptation is the “phase III” detoxifying mechanism that  
consists of transporter proteins. Phase III proteins include  
multidrug resistance proteins (MDRs), organic anion  
transporters (OATs) and organic cation transporters (OCTs). 
The warfare between possums and Eucalyptus plants is an 
illuminating example of an effective animal detoxification 
system. Possums ingest doses of up to 10 g of 1,8-cineole per 
day, doses which would be quite poisonous for human beings. 
Terpenes act as inducers of their own metabolism by positive 
feedback.55 Animals which have been fed ten days with a  
terpene-diet showed a 53% increase in CYP450 enzymes. The 
terpenes are metabolized into 19 different metabolites, which 
are excreted in free or glucuronidated form.62 On the other 
hand, Eucalyptus trees have reduced their attractiveness for 
herbivores: Beside their high content of toxic oils, they contain 
only low amounts of protein and high lignin fiber. 
PSM influence on gene expression has been observed in 
many other plants. A prominent representative is St. John’s 
Wort, whose constituent ingredients increase CYP3A4 and  
P-glycoprotein (MDR1) levels in herbivores.63 Another  
interesting point is that chlorophyll is an inducer of phase II 
enzymes,64 which are responsible for improved elimination of 
transformed xenobiotics. This up-regulation of enzymes  
supporting the excretion of toxins led to the hypothesis of a 
reversal effect: animals may use certain PSMs for protection 
against other toxic plant compounds. 
The evolution of natural pro-drugs can be viewed as a result 
of improved detoxifying systems in animals. The effectiveness 
of CYP450 to dispose the plants’ toxins made it necessary to 
develop strategies which are able to skirt the animals’ defense. 
These so called pro-drugs allow plants to co-opt the animal 
detoxification system to increase the effectiveness of their own 
toxins and therefore their chance of survival. The underlying 
principle is that the plants use these detoxifying enzymes as 
tool to activate non-toxic PSMs into toxic metabolites within 
animal cells. Taking into account that the main detoxification 
organ is the liver, hepatotoxicity is a frequent consequence of 
metabolism of these pro-drugs.65 
 
3 Metabolic Detoxification Systems of Animals 
Because of the extraordinary importance of metabolic  
detoxification of PSM in animals, we focus in more detail on 
the large superfamily of cytochrome P450 (CYP450) enzymes 
and their role in plant-herbivore interaction. Present in almost 
all eukaryotes and prokaryotes, the functional spectrum of 
CYP450 enzymes is much broader than simply detoxifying 
exogenous plant compounds. In fact, CYP450 enzymes are 
even involved in the synthesis of PSMs in plants, as well as in 
the conversion of other endogenous substrates such as  
hormones or vitamin D3, and in basic cellular functions such as 
cell growth and apoptosis.66 
The CYP450 enzymes are a family of heme-thiolate  
proteins with a characteristic absorption at 450nm while they 
bind a CO-molecule as the sixth ligand in a characteristic  
low-spin heme-thiolate-iron-complex. More than 2000  
members of this superfamily of enzymes have been identified. 
The CYP450 enzymes are essential for elimination of  
exogenous xenobiotic compounds. Therefore, the highest  
expression of CYP450 enzymes in herbivores can be found in 
excretory systems, i.e. liver, kidney and the gastrointestinal 
endothelium.7 In phase I of the elimination process, CYP450 
enzymes catalyze oxidation reactions of hydrophobic toxins, 
leading to reactive hydroxy groups, which can then be used as 
a “clutch” between the toxins and hydrophilic, water soluble 
acceptor molecules such as glucose, glucuronic acid, sulfate 
and glutathione.67 The latter is described as Phase II  
metabolism and consists of a conjugation reaction of acceptor 
molecules with the mentioned agents to ethers and esters, 
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Figure 2.  The animal plant warfare system as a mutual correlation 
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which provides the basis for elimination by the kidney through 
their high hydrophilic properties. 
Likely as a result of various selective advantages during 
evolution, CYP450 enzymes are subject to numerous  
egulatory mechanisms. In many cases, substrate molecules act 
as inducing agents of CYP450 enzymes,67 e.g. 3, 4-
benzo(a)pyrene.68,69 This polycyclic aromatic hydrocarbon is 
able to activate a specific cytoplasmic receptor, the aryl  
hydrocarbon receptor (AhR), which, after binding to its ligand 
and dimerizing with another binding partner, translocates into 
the nucleus. Here, AhR enhances the expression of CYP1A1 
and the metabolism of 3,4-benzpyrene. Polycyclic aromatic 
hydrocarbons are also responsible for the enhanced expression 
of phase II genes such as UDP-glucuronosyl transferase and 
glutathione S-transferase, leading to a strategic connection 
between phase I and phase II reactions via the so-called “Ah 
gene battery”.67 Another example of transcriptional induction 
is the activation of the pregnane x receptor by hyperforin from 
St John’s Wort (Hypericum perforatum L.), which causes an 
increase in CYP3A4 and the drug efflux protein P-
glycoprotein. This represents a connection between phase I 
and phase III reactions for xenobiotic elimination.7  
Furthermore, there is evidence for regulation on the  
post-transcriptional level via protein stabilization by ethanol, 
acetone or pyrazole.67,70 Gender-specific signals also seem to 
influence CYP450 expression.71 
The genetic evolution of CYP450 was of immense  
importance in animal plant warfare because it generated  
dietary selective pressures responsible for both the  
development of toxic metabolites in plants and their  
detoxification in animals.67 As ancestral CYP genes arose 
about 3.5 billion years ago, their probable first role was to 
detoxify oxygen in a reducing atmosphere. Along with the rise 
of atmospheric oxygen and the shift to an oxidizing  
atmosphere, a non-linear correlation between the O2 level and 
the evolution of CYP450 genes took place.72 About 400  
million years ago, several evolutionary forces led to the  
emergence of many CYP450 families involved in xenobiotic 
metabolism. At this time, the oxygen level was about 50% of 
that in the present atmosphere and eukaryotes entering the 
emerging land masses experienced dietary changes and were 
exposed to new plant xenobiotics.73 Furthermore, the  
atmosphere was enriched in hydrocarbon combustion products. 
Both sources of toxins necessitated effective detoxification 
systems, which resulted in new adaptations to changing  
nutritional sources and environments.72 
What were the molecular basics of evolution in the CYP 
gene superfamily? The major force that expedited this  
development is a phenomenon called “molecular drive,” which 
is a distribution of new gene variants in a population as a  
consequence of genomic turnover mechanisms.67 Independent 
from natural selection and genetic drift,74,75 this internal  
irregular DNA behavior may be a major reason for CYP450 
evolution. The mechanism of molecular drive is gene  
duplication, which provides ample opportunity for the  
establishment of mutations. Whereas one gene copy inherits its 
original function and must maintain the ability to facilitate 
necessary cellular processes (a process called ‘conservative 
selection pressure’),76 the other copy is free to drift, often  
resulting in a pseudogene, a gene that encodes for a  
nonfunctional protein. The two copies of the duplicated gene 
are termed paralogues: related genes arisen by gene  
duplication. On a molecular level, duplication happens through 
a polymerase shift. During DNA-replication, the replicated 
strand may experience a backshift because of repeated  
elements on the original strand, leading to a loop with  
duplication of a specific DNA sequence. In contrast, a forward 
step by the polymerase creates a loop in the original strand, 
leading to a deletion.76 The duplicated gene is able to diverge 
or drift due to mutations. Expedient mutations are fixed,  
causing evolutionary advantages such as allowing  
metabolization or synthesis of PSMs.71 Such evolutionary and 
counter-evolutionary adaptations have continued in a vicious 
cycle in enzyme development between plants and herbivores 
for at least 800 million years. The genes are now considered 
orthologues, i.e. genes in different genomes with a common 
phylogenetic ancestor. 
The evolution of CYP450 by molecular drive can be  
illustrated by the CYP2D subfamily. About 1.1 billion years 
ago, CYP2D and other subfamilies emerged though gene  
duplication events.71 About 80 million years ago, the split  
between humans and rodents resulted in marked differences 
between the enzymatic accoutrements within the two species. 
While the rat genome contains five active CYP2D genes,  
human beings possess one active gene and four pseudogenes.66 
The genetic differences between rats and humans are relevant 
in pharmacology, since results from drug-testing in rodents 
may be not directly translatable to drug activity in humans. 
Caucasian CYP2D6 deficiency is a well-examined genetic 
polymorphism, which explains why about 10% of the  
Caucasian population in Europe and North America are unable 
to efficiently metabolize debrisoquine and other plant  
alkaloids.77 The inactivation of CYP2D6 led to the hypothesis 
that the gene might be predisposed to extinction, because it 
rose up during evolutionary animal-plant warfare, but modern 
civilization requires less dietary alkaloid detoxification.77 
In general, polymorphisms are common among CYP450s. It 
is probable that all human CYP450 genes are subject to  
inter-individual variation, as a result of the enormous genetic 
diversity of the human species.72 One reason for the  
establishment of polymorphisms may be a lack of co-
evolutionary pressures. An illustrative example is the CYP2D6 
polymorphisms that lead to extensive and poor metabolizers of 
certain drugs. Extensive metabolizers of debrisoquine show 
10-200 times higher metabolite concentration in their urine 
than poor metabolizers.72 There is no self-evident advantage 
for bearing a functionalized gene without drug exposure. In 
contrast, there is a heightened risk of lung cancer for tobacco 
smokers who have the extensive CYP2D6 metabolization  
polymorphism.66,72 
One approach to measuring these evolutionary incidents are 
the “per site substitutions per 109 years”, meaning the statisti-
cal frequency of exchange of a DNA base at a specific site in 
one billion years. A number of different types of mutations can 
be defined. Synonymous mutations results in no change in the 
amino acid sequence encoded, whereas non-synonymous  
mutations cause an amino acid change and therefore can  
influence protein structure and function. Silent mutations  
occur more frequently than do non-silent ones, since they are 
not subjected to selective pressures. For proteins with strong 
functional constraints, e.g. histones, relatively small numbers 
of per site substitutions per 109 years (0.004 for  
non-synonymous and 1.43 for synonym mutations) have been 
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reported. In contrast to these highly conserved genes, the 
CYP2D6 cluster belongs to a group of rapidly-evolving genes 
with non-synonymous rates of 1.25 and synonymous rates of 
3.91 per site substitutions per 109 years.77 It is interesting that 
pseudogenes have similar rates of synonymous and non-
synonymous mutations. This can be explained by the fact that 
selection pressures of evolution do not downsize the number 
of non-synonymous mutations, because pseudogenes have no 
function and therefore are free to drift. On the other hand, an 
active copy is able to inherit the essential function.77 
 
4 Conclusion and Perspectives 
The co-evolutionary adaptation process among higher  
organisms termed animal plant warfare has resulted in a huge 
array of bioactive chemical compounds in plants. Because the 
primary function of these phytochemicals is defense against 
predators, it comes as no surprise that many of them are toxic 
to humans. However, a fraction of these plant secondary  
metabolite compounds exert valuable pharmacological actions 
and can be exploited for medicinal purposes. Medicinal plant 
and herbal preparations are frequently advertised as having 
fewer side effects than chemically synthesized drugs. This 
claim must be taken with much caution, as beneficial medicinal
effects were of course no target for evolutionary selection  
during the history of animal plant warfare. Therefore, it is an 
important task of modern pharmaceutical sciences to analyze 
the molecular and cellular modes of action of plants used for 
medicinal purposes and to distinguish beneficial pharmacolog-
ical effects from adverse toxic side effects. This is no trivial 
task, as plants contain complex mixtures of phytochemicals 
that interact in the human body, potentially leading to  
synergistic and/or antagonistic effects. The mechanistic  
understanding of such interactions may also be exploitable for 
pharmacological purposes. Plant chemical substances able to 
inhibit drug transport processes in plants might also serve as 
inhibitors of human ABC transporters. Drug pumps such as P-
glycoprotein (ABCB1/MDR1), MRP1 (ABCC1), BCRP 
(ABCG2) and others play an important role in physiological 
processes (e.g. in the blood brain barrier) and diseases (e.g. in 
multidrug-resistant tumors). Hence, chemical scaffolds with 
inhibitory activity towards ABC transporters in plants may be 
able to serve as lead structures for development of drugs 
against ABC transporters in human diseases. Other examples 
are inhibitors of signal transduction molecules (e.g. kinase 
inhibitors) or inhibitors of apoptosis (e.g. caspase inhibitors).78 
A deeper understanding of molecular and cellular interactions 
of phytochemicals and human disease processes opens new 
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